^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Excerpt:
A proposed treatment algorithm for the management of hormone receptor (HR)-positive, HER2-negative MBC...Recommendations...Beyond second line...The combination of a taxane or capecitabine with bevacizumab, if available, is an option for the first line of ChT...
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Source:
Title:
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Excerpt:
...(Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)...
Trial ID:
Source:
Title:
Eribulin in HER2 Negative Metastatic BrCa
Excerpt:
...- Hormone receptor positive or hormone receptor negative HER2-negative disease...
Trial ID:
More C2 evidence
Source:
Title:
Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer
Excerpt:
...- Histologically or cytologically confirmed locally advanced or metastatic HER2-neg, hormone receptor positive or negative adenocarcinoma of the breast with measurable or evaluable disease according to RECIST 1.1 criteria...
Trial ID:
Less C2 evidence
Source:
Title:
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer
Published date:
10/10/2023
Excerpt:
The CBR at 3 months in patients with HR + /HER2- disease was 83.9% (n = 31), and 12.9% of patients had a PR. The median PFS was 18.1 weeks. In the 12 patients with TNBC, the CBR was 66.7% with a PR rate of 25%. The median PFS was 10.8 weeks. As expected, PFS was longer in those with HR + disease versus those with TNBC (18.1 vs 10.8 weeks; p = 0.067)...In conclusion, the results of this trial demonstrate that EC has antitumoral activity in heavily pretreated patients with locally ABC or MBC.
Secondary therapy:
cyclophosphamide
DOI:
https://doi.org/10.1007/s10549-023-07073-0
Trial ID:
Source:
Title:
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)
Published date:
07/22/2023
Excerpt:
In this prospective phase II trial of patients with luminal MBC, we administered biweekly eribulin to...Sixty patients with hormone-receptor-positive and HER2-negative MBC were enrolled...In addition, the PFS from the enrollment date for patients who received maintenance therapy was 25.29 weeks (19.14–32.14). Furthermore, among patients who achieved CR or PR during induction therapy, PFS starting on the first day of maintenance therapy was significantly longer than that of patients with SD (49.00 weeks vs. 14.14 weeks p = 0.0062)...
DOI:
https://doi.org/10.1007/s10549-023-07030-x
Source:
Title:
Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.
Published date:
05/25/2023
Excerpt:
...in this real-world study, we retrospectively assessed the clinical outcomes of Chinese patients with MBC who received eribulin….By molecular classification, the ORR of patients with HR+/HER2− disease was 66.7%...
DOI:
10.1200/JCO.2023.41.16_suppl.e13126
Source:
Title:
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).
Published date:
05/25/2023
Excerpt:
Pts (≥18 years) diagnosed with HR+/HER2- mBC….Capecitabine and paclitaxel were the most used as the first (45% and 29%), second (35% and 30%), and third (25% and 22%) CT, while gemcitabine (22%) and eribulin (20%) were used most as fourth CT....Median real-world overall survival (rwOS; 95% CI) from time of mBC diagnosis was 48.5 months (45.5-51.5). Median rwOS from first CT treatment start date was 23.3 months (21.3-25.4). In pretreated pts with 1, 2, or 3 prior lines of CT, median rwOS from each index date was 16.5 months (14.8-18.3), 11.8 months (10.4-13.1), and 9.1 months (7.3-11.2), respectively.
DOI:
10.1200/JCO.2023.41.16_suppl.e18871
Source:
Title:
Effectiveness and safety of eribulin as a front-line treatment in advanced breast cancer patients in China: A prospective real-world study.
Published date:
05/26/2022
Excerpt:
In HR+/HER2- ABC, eribulin monotherapy was used; in HER2+ ABC, eribulin plus anti-HER2 targeted therapy were used...Eribulin monotherapy or combined with targeted therapy was effective and well-tolerated as the first to third lines of treatment in ABC.
DOI:
10.1200/JCO.2022.40.16_suppl.e13015
Trial ID:
Source:
Title:
Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population
Published date:
09/24/2021
Excerpt:
...patients with human epidermal growth factor receptor-2-negative metastatic breast cancer which assesses effectiveness and safety of eribulin...Its benefit seems to be higher in patients with hormonal receptor expression and patients who had received capecitabine prior to eribulin.
DOI:
https://doi.org/10.1177/10781552211038241
Source:
Title:
The effectiveness and safety of eribulin therapy in HR-positive HER2-negative metastatic breast cancer post-CDK4/6 inhibitor therapy in Russian clinical practice.
Published date:
05/19/2021
Excerpt:
Observation study of eribulin monotherapy in standard regimen enrolled 54 pts (median age 56; range 29-79 years) with HR+ HER2- MBC received at least one dose of eribulin post CDK 4/6i in metastatic settings...Patients with metastasis to the lung have better mPFS. Results in this real-world population of pts with HR+HER2- MBC were consistent with the EMPOWER study, and support administration of eribulin in 2-3 lines as an effective option for post-CD4/6i pts.
DOI:
10.1200/JCO.2021.39.15_suppl.e13035
Source:
Title:
116P - Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2- metastatic breast cancer patients in the United States
Published date:
05/03/2021
Excerpt:
Best overall response on eribulin was 52% and median PFS for eribulin was estimated at 6.1 months. Landmark OS at 12 and 24 months was 46% and 26%, respectively. Approximately 31% (n=72) of the HR+/HER2- mBC patients had received a CDKi prior to eribulin. In the post CDKi subgroup, median duration of eribulin treatment was 4.5 months, and 74% were treated in 4th line or later. Best overall response on eribulin was 40%. Median PFS for eribulin in the post CDKi subgroup was estimated to be 4.6 months. Landmark OS at 12 and 24 months in the post CDKi subgroup was 39% and 19%, respectively.
